Association between genetic polymorphism of Prostaglandin-mediated drug enzymes, transporters and receptor and disease susceptibility and response to Latanoprost

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCC-11001326

Enrollment

Unknown

Registered

2011-03-29

Start date

2011-05-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

Group A:Latanoprost

Group B:Health control

Eligibility

Sex/Gender

All

Age

16 Years to 89 Years

Inclusion criteria

Inclusion criteria: Glaucoma patients (case group), no eye disease (healthy subjects group).

Exclusion criteria

Exclusion criteria: Glaucoma patients with other chronic diseases (case group), other eye diseases and chronic diseases (healthy subjects group).

Design outcomes

Primary

Measure	Time frame
IOP (Baseline intraocular pressures);	—

Countries

China

Contacts

Public ContactHonghao Zhou

hhzhou2003@163.com+86 731 84805380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026